Overview

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Status:
RECRUITING

Trial end date:
2027-08-15

Target enrollment:

Participant gender:

Summary

Study to assess the safety, pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body) of RN3161 alone (healthy volunteers) and RN3161 with tirzepatide (overweight and obese subjects)

Phase:

PHASE1

Details

Lead Sponsor:

Ikaria Bioscience Pty Ltd

Collaborator:

Shanghai Rona Therapeutics Co., Ltd.

Treatments:

Tirzepatide